Trial Profile
A multiple ascending dose safety and pharmacokinetic trial of the intravenous (IV) formulation of TPOXX (tecovirimat) for the treatment of orthopoxvirus disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2016
Price :
$35
*
At a glance
- Drugs Tecovirimat (Primary)
- Indications Orthopoxvirus infections
- Focus Adverse reactions; Pharmacokinetics
- 22 Mar 2016 New trial record